Two things, I doubt any company that integrates this into

New Post Public Reply Private Reply Replies (0) Message Board
nFUSZmywallet21 Mauibound #15869
545
Two things, I doubt any company that integrates this into their platform is paying on the lower end of the 30-150k price range, it’ll me more around the higher end. Another is if it’s ready for PrimeMyBody I wonder how many other companies launched within the past few days and weeks since last PR. Company has been quietly working their butts off and we will soon see the rewards.

Another thing that just popped into my head. With Q2 numbers coming out Rory said he will have guidance for the rest of the year. I believe that is partly to do with the tech being ready for, as you said, plug n play, and more than likely many companies starting to pay around this time, end of Q2, beginning of Q3.

Then with guidance comes analysts imo, and like red said, they’re not putting any $2 price tag on us that’s for sure.

I look at $10 as a base price to estimate where we will be by end of year, beginning of 2020. $10 is 220 million market cap. That’s about 14 times our run rate of 16 million, which I believe we surpass.

But at $10 we are below the average revenue multiple of 16.8 with our run rate alone, that says something to me.

Now think about what if Q2 is
4.5 million 12.5% increase
5 million 25% increase
5.5 million 37.5% increase
6 million 50% increase

What do the numbers look like then, because at just our run rate, $10 even seems a bit low

Something to think about

TON Strategy Co. (TONX) Stock Research Links

TONX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Lumexa Imaging's Investor Conference Push: Any Real Substance?

Updated Category News Views 132

Lumexa Imaging just dropped a line on Feb 17, 2026, about their upcoming investor conference gigs. Sure, they're strutting into multiple events—Raymond James in Orlando, Leerink Partners in Miami, and Barclays back-to-back days after that. But here’s the kicker: are these talks really worth the buzz? In a space where outpatient imaging claims to be kingpin, you’ve...

Continue Reading
Current Landscape of US Stock Futures Amid Rate Cuts

Updated Category News Views 173

Insights on the Current Stability of U.S. Stock Futures During Asian trading hours, U.S. stock index futures have held steady. Investors are hoping for interest rate cuts as the Federal Reserve's next meeting approaches. This meeting is expected to reveal a significant easing cycle that many in the market are eagerly anticipating. Even with strong reports on consumer and...

Continue Reading
Wispr Flow Revolutionizes Voice Dictation Across Platforms

Updated Category News Views 469

Wispr Flow Expands Its Reach in Voice Dictation Technology In a world where speed and efficiency are paramount, Wispr, known as The Voice Interface Company, is revolutionizing the way we interact with technology. With the recent launch of Wispr Flow for Windows, this innovative voice productivity tool is now accessible to users across both Mac and Windows platforms,...

Continue Reading
MintMiner: Your Ultimate Gateway to Cloud Mining Success

Updated Category News Views 197

Unlocking the Future of Cloud Mining with MintMiner In today's uncertain financial landscape, MintMiner presents an innovative solution for anyone looking to tap into the world of digital assets. As global financial systems face challenges, MintMiner offers a unique platform that makes cloud mining accessible, straightforward, and profitable. Understanding Cloud Mining...

Continue Reading
GT Biopharma's Strategic Move: Withdrawal of S-1 Registration

Updated Category News Views 100

GT Biopharma's Strategic Withdrawal of Form S-1 Registration GT Biopharma, Inc. (NASDAQ: GTBP) recently made headlines with its request for withdrawal of a Form S-1 registration statement. This decision marks a crucial moment for the company, based in San Francisco, known for its innovative approach in the immuno-oncology sector. GT Biopharma focuses on the development of...

Continue Reading